Edition:
United Kingdom

Endologix Inc (ELGX.OQ)

ELGX.OQ on NASDAQ Stock Exchange Global Select Market

0.98USD
7:48pm GMT
Change (% chg)

$-0.04 (-3.48%)
Prev Close
$1.02
Open
$1.02
Day's High
$1.03
Day's Low
$0.95
Volume
269,460
Avg. Vol
192,784
52-wk High
$6.71
52-wk Low
$0.92

Latest Key Developments (Source: Significant Developments)

Endologix Reports Q3 Revenue $34.8 Million
Thursday, 1 Nov 2018 

Nov 1 (Reuters) - Endologix Inc ::ENDOLOGIX REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS.SEES FY 2018 GAAP LOSS PER SHARE $0.87 TO $0.91.Q3 LOSS PER SHARE $0.12.Q3 REVENUE $34.8 MILLION VERSUS I/B/E/S VIEW $34.5 MILLION.SEES FY 2019 REVENUE AT LEAST $140 MILLION.Q3 EARNINGS PER SHARE VIEW $-0.24 -- THOMSON REUTERS I/B/E/S.CONTINUES TO ANTICIPATE 2018 REVENUE IN RANGE OF $150 MILLION TO $155 MILLION.2019 OPERATING EXPENSES ANTICIPATED TO BE IN RANGE OF $130 MILLION TO $140 MILLION.FY2019 REVENUE VIEW $142.7 MILLION -- THOMSON REUTERS I/B/E/S.FY2018 REVENUE VIEW $151.7 MILLION -- THOMSON REUTERS I/B/E/S.FY2018 EARNINGS PER SHARE VIEW $-0.79 -- THOMSON REUTERS I/B/E/S.  Full Article

Endologix Announces Public Offering Of Common Stock
Wednesday, 24 Oct 2018 

Oct 24 (Reuters) - Endologix Inc ::ENDOLOGIX ANNOUNCES PUBLIC OFFERING OF COMMON STOCK.ENDOLOGIX INC - COMMENCED A REGISTERED UNDERWRITTEN PUBLIC OFFERING OF $20.0 MILLION OF ITS SHARES OF COMMON STOCK.ENDOLOGIX - INTENDS TO USE NET PROCEEDS FROM OFFERING TO REDEEM ALL $18.3 MILLION 2.25% CONVERTIBLE SENIOR NOTES DUE 2018.  Full Article

FDA Classifies Previous Endologix Afx Safety Notice As Class I Recall
Friday, 5 Oct 2018 

Oct 5 (Reuters) - Endologix Inc ::FDA CLASSIFIES PREVIOUS ENDOLOGIX AFX SAFETY NOTICE AS CLASS I RECALL.ENDOLOGIX- RECEIVED NOTICE THAT FDA CLASSIFIED VOLUNTARY RECALL ACTION THAT CO TOOK IN JULY OF THIS YEAR AS A CLASS I RECALL.ENDOLOGIX INC - JULY RECALL INVOLVED CO'S ISSUANCE OF A SAFETY NOTICE TO HEALTHCARE PROFESSIONALS USING AFX ENDOVASCULAR AAA SYSTEM.ENDOLOGIX - NO PRODUCT WAS REMOVED FROM FIELD AS PART OF JULY RECALL.  Full Article

Endologix Announces Q3 Revenue Results, Raises Low-End Of FY Revenue Guidance
Tuesday, 2 Oct 2018 

Oct 2 (Reuters) - Endologix Inc ::ENDOLOGIX ANNOUNCES THIRD QUARTER PRELIMINARY REVENUE RESULTS AND RAISES LOW END OF 2018 REVENUE GUIDANCE RANGE.SEES Q3 2018 REVENUE $34.3 MILLION TO $34.7 MILLION.NOW ANTICIPATES 2018 REVENUE TO BE IN RANGE OF $150 MILLION TO $155 MILLION.  Full Article

Japan Lifeline says termination of joint research and development contract on Thoracic Stent Grafts
Friday, 28 Sep 2018 

Sept 28(Reuters) - Japan Lifeline Co Ltd <7575.T>:Says it has reached agreement with Endologix Inc <<>> to terminate the joint development contract related to thoracic stent graft system as of October 1.The joint product development agreement related to thoracic stent graft system was signed by the parties in September 2017.In conjunction with the termination of the contract related to development of a thoracic stent graft system, the two companies have also agreed to terminate the exclusive sales agreement for Japan concerning the thoracic stent graft system.  Full Article

Endologix Reports Q2 Loss Per Share Of $0.28
Thursday, 9 Aug 2018 

Aug 9 (Reuters) - Endologix Inc ::ENDOLOGIX REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS.SEES FY 2018 GAAP LOSS PER SHARE $1.04 TO $1.12.Q2 LOSS PER SHARE $0.28.SEES FY 2018 REVENUE $145 MILLION TO $155 MILLION.Q2 REVENUE $44.7 MILLION VERSUS I/B/E/S VIEW $44.4 MILLION.Q2 EARNINGS PER SHARE VIEW $-0.15 -- THOMSON REUTERS I/B/E/S.TOTAL CASH, CASH EQUIVALENTS, AND RESTRICTED CASH WERE $37.6 MILLION AS OF JUNE 30, 2018.FY2018 EARNINGS PER SHARE VIEW $-0.58, REVENUE VIEW $175.8 MILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Endologix Inc Files For Mixed Shelf Of Upto $100 Million
Thursday, 31 May 2018 

May 31 (Reuters) - Endologix Inc ::ENDOLOGIX INC FILES FOR MIXED SHELF OF UPTO $100 MILLION - SEC FILING.  Full Article

Endologix Q3 loss per share $0.17
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Endologix Inc ::Endologix reports third quarter 2017 financial results.Sees FY 2017 gaap loss per share $0.91 to $0.93.Q3 loss per share $0.17.Sees FY 2017 revenue $181 million to $184 million.Q3 revenue $46 million versus I/B/E/S view $46.7 million.Q3 earnings per share view $-0.17 -- Thomson Reuters I/B/E/S.  Full Article

Endologix says operations not materially affected by Santa Rosa fires‍​
Thursday, 12 Oct 2017 

Oct 12 (Reuters) - Endologix Inc : :Comments on impact of the Santa Rosa fires impact on co's facility ‍​.Co's Santa Rosa, California-based facility that manufactures and develops its ovation product line is safe and secure.Says it operations have not been materially affected by the Santa Rosa fires.Endologix Inc says it resumed shipments from its Santa Rosa facility on Oct 10, following a brief delay, and plans to resume manufacturing soon.Endologix Inc says many of the company’s Santa Rosa employees have been adversely impacted by the fire.  Full Article

COLUMBIA WANGER ASSET MANAGEMENT REPORTS 7.6 PCT PASSIVE STAKE IN ENDOLOGIX INC AS OF DEC 31, 2016
Friday, 10 Feb 2017 

Columbia Wanger Asset Management LLC:COLUMBIA WANGER ASSET MANAGEMENT LLC REPORTS 7.6 PERCENT PASSIVE STAKE IN ENDOLOGIX INC AS OF DEC 31, 2016 - SEC FILING.  Full Article